Cantor Fitzgerald maintains $118 target on Ultragenyx stock
Cantor Fitzgerald reaffirmed its Overweight rating and $118.00 price target for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company specializing in rare diseases. Currently ...
Cantor Fitzgerald cuts Informatica price target to $18 from $29
Cantor Fitzgerald adjusted its outlook on Informatica (NYSE:INFA) shares by lowering the price target to $18.00 from the ...
Phathom Pharmaceuticals initiated at Cantor Fitzgerald on ‘significant’ upside
Cantor Fitzgerald initiated coverage of Phathom Pharmaceuticals (PHAT) with an Overweight rating and $23 price target The firm cited ...
Seabridge Gold Announces US$100 Million in Financings Includes US$20 million from Strategic Investor
Seabridge Gold Inc. (TSX: SEA) (NYSE: SA) ("Seabridge" or the "Company") announced today it has entered into an agreement with RBC Capital Markets and Cantor Fitzgerald Canada Corporation (together ...
Cantor Fitzgerald Remains a Buy on Kornit Digital (KRNT)
In a report released yesterday, Troy Jensen from Cantor Fitzgerald reiterated a Buy rating on Kornit Digital (KRNT – Research Report), with a ...
CVS Health upgraded at Cantor Fitzgerald after Q4 beat
CVS Health (CVS) stock was upgraded by Cantor Fitzgerald to Overweight after the company posted strong Q4 results earlier in ...
Deal Watch: Deals Keep Moving, But M&A Value Fell in January
M&A markets don't like volatility and unpredictability, and what we've seen in the past few weeks is the opposite of that,” ...